Re: New RVX Tweet
in response to
by
posted on
Jul 28, 2020 07:56PM
KK2 - From the June 22 PR - BoM2
All or most BETonMACE2 patients to receive top standard of care, including maximized use of SGLT2 inhibitors (SGLT2i)
BETonMACE2 to increase enrichment of chronic kidney disease (CKD) patients, potentially including those with lower baseline renal function
Based on BETonMACE results, the FDA encouraged the evaluation of a non-alcoholic fatty liver disease (NAFLD) subgroup as well as related exploratory endpoints
Just some small changes that could have a profound effect on the final outcome as it was these groups that had the best results in BETonMACE.
Best to have the scientists chime in as I am not in that catagory.
tada